Celldex Therapeutics Inc. [NASDAQ: CLDX] price plunged by -12.06 percent to reach at -$4.94.
The one-year CLDX stock forecast points to a potential upside of 46.86. The average equity rating for CLDX stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Celldex Therapeutics Inc. [CLDX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLDX shares is $67.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLDX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Celldex Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 18, 2024. While these analysts kept the previous recommendation, Wolfe Research raised their target price to Outperform. The new note on the price target was released on June 11, 2024, representing the official price target for Celldex Therapeutics Inc. stock.
The Average True Range (ATR) for Celldex Therapeutics Inc. is set at 3.24, with the Price to Sales ratio for CLDX stock in the period of the last 12 months amounting to 287.68. The Price to Book ratio for the last quarter was 2.93, with the Price to Cash per share for the same quarter was set at 12.03.
CLDX Stock Performance Analysis:
Celldex Therapeutics Inc. [CLDX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.93. With this latest performance, CLDX shares dropped by -4.46% in over the last four-week period, additionally sinking by -12.23% over the last 6 months – not to mention a rise of 39.40% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLDX stock in for the last two-week period is set at 37.45, with the RSI for the last a single of trading hit 29.42, and the three-weeks RSI is set at 42.17 for Celldex Therapeutics Inc. [CLDX]. The present Moving Average for the last 50 days of trading for this stock 38.46, while it was recorded at 39.91 for the last single week of trading, and 38.87 for the last 200 days.
Insight into Celldex Therapeutics Inc. Fundamentals:
Celldex Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 29.36 and a Current Ratio set at 29.36.
Celldex Therapeutics Inc. [CLDX] Institutonal Ownership Details
There are presently around $107.31%, or 107.63%% of CLDX stock, in the hands of institutional investors. The top three institutional holders of CLDX stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 8.08 million shares, which is approximately 13.718%. FMR LLC, holding 7.83 million shares of the stock with an approximate value of $$289.76 million in CLDX stocks shares; and FMR LLC, currently with $$173.61 million in CLDX stock with ownership which is approximately 7.9679%.
